Prognostic factors in ovarian cancer: Current evidence and future prospects

European Journal of Cancer, Supplement

Volumn 1, Issue 6 SPEC. ISS., 2003, Pages 127-145

  Crijns, A P G ^a   Boezen, H M ^a   Schouten, J P ^a   Arts, H J G ^a   Hofstra, R M W ^a   Willemse, P H B ^a   De Vries, E G E ^a   Van Der Zee, A G J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL FACTOR; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUTATHIONE TRANSFERASE; PROTEIN TYROSINE KINASE;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CONFERENCE PAPER; DNA MICROARRAY; GENE EXPRESSION PROFILING; HUMAN; MEDICAL DECISION MAKING; MOLECULAR BIOLOGY; OVARY CARCINOMA; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEIN FAMILY; RISK ASSESSMENT; STATISTICAL ANALYSIS;

EID: 5144220224     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)90017-6     Document Type: Conference Paper

References (153)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics, 2003. CA Cancer J Clin. 53:2003;5-26
2. Trimbos J.B., Parmar M., Vergote I., et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 95:2003;105-112
3. Mills G.B., Schmandt R., Gershenson D., Bast R.C. Should therapy of ovarian cancer patients be individualized based on underlying genetic defects? Clin Cancer Res. 5:1999;2286-2288
4. Konecny G., Fritz M., Untch M., et al. HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. Breast Cancer Res Treat. 69:2001;53-63
5. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:2001;783-792
6. Aunoble B., Sanches R., Didier E., Bignon Y.J. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer. (review) Int J Oncol. 16:2000;567-576
7. Ciardiello F., Caputo R., Bianco R., et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptorselective tyrosine kinase inhibitor. Clin Cancer Res. 6:2000;2053-2063
8. Tortora G., Caputo R., Damiano V., et al. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clin Cancer Res. 7:2001;4156-4163
9. Finn R.S., Beryt M., Konecny G., Pegram M.D., Slamon D.J. ZD1839 ("Iressa") acts synergistically with chemotherapy in ovarian cancer cells expressing high levels of the epidermal growth factor receptor. Proc Am Soc Clin Oncol. 2002;. #1928
10. Christen R.D., Hom D.K., Porter D.C., et al. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest. 86:1990;1632-1640
11. Cenni B., Aebi S., Nehme A., Christen R.D. Epidermal growth factor enhances cisplatin-induced apoptosis by a caspase 3 independent pathway. Cancer Chemother Pharmacol. 47:2001;397-403
12. Aigner A., Hsieh S.S., Malerczyk C., Czubayko F. Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol. Toxicology. 144:2000;221-228
13. Ueno N.T., Bartholomeusz C., Herrmann J.L., et al. EIA-mediated paclitaxel sensitization in HER-2/neuoverexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 6:2000;250-259
14. Hancock M.C., Langton B.C., Chan T., et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 51:1991;4575-4580
15. Pietras R.J., Fendly B.M., Chazin V.R., Pegram M.D., Howell S.B., Slamon D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian can-cer cells. Oncogene. 9:1994;1829-1838
16. Bauknecht T., Runge M., Schwall M., Pfleiderer A. Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas. Gynecol Oncol. 29:1988;147-157
17. Kohler M., Janz I., Wintzer H.O., Wagner E., Bauknecht T. The expression of EGF receptors, EGF-like factors and c-myc in ovarian and cervical carcinomas and their potential clinical significance. Anticancer Res. 9:1989;1537-1547
18. Berchuck A., Rodriguez G.C., Kamel A., et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol. 164:1991;669-674
19. van Dam P.A., Vergote I.B., Lowe D.G., et al. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol. 47:1994;914-919
20. Scambia G., Benedetti-Panici P., Ferrandina G., et al. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer. 72:1995;361-366
21. Devitt J.L., Chew K., Sauter G., Waldman F., Benz C.C. Prevalence and prognostic significance of HER2/neu and epidermal growth factor receptors in ovarian cancer. J Exp Clin Cancer Res. 14:1995;329-334
22. Meden H., Marx D., Raab T., Kron M., Schauer A., Kuhn W. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. J Obstet Gynaecol. 21:1995;167-178
23. Bartlett J.M., Langdon S.P., Simpson B.J., et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer. 73:1996;301-306
24. Fischer-Colbrie J., Witt A., Heinzl H., et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res. 17:1997;613-619
25. Kamel N.A.M.H. Epidermal growth factor receptor in ovarian cancer: detection and prognostic value. Cancer Mol Biol. 4:1997;1003-1012
26. Baekelandt M., Kristensen G.B., Trope C.G., Nesland J.M., Holm R. Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer. Anticancer Res. 19:1999;4469-4474
27. Skirnisdottir I., Sorbe B., Seidal T. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer. 11:2001;119-129
28. Nagai N., Oshita T., Fujii T., Katsube Y., Matsubayashi S., Ohama K. Are DNA ploidy and epidermal growth factor receptor prognostic factors for untreated ovarian cancer? A prospective study. Am J Clin Oncol. 24:2001;215-221
29. Herbst R.S., Maddox A.M., Rothenberg M.L., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZDl839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 20:2002;3815-3825
30. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 19:2001;3267-3279
31. Seiden M.V. Ovarian cancer. Oncologist. 6:2001;327-332
32. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712
33. Berchuck A., Kamel A., Whitaker R., et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50:1990;4087-4091
34. Kacinski B.M., Mayer A.G., King B.L., Carter D., Chambers S.K. NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. Gynecol Oncol. 44:1992;245-253
35. Scambia G., Benedetti P.P., Ferrandina G., et al. Expression of HER-2/neu oncoprotein, DNA-ploidy and S-phase fraction in advanced ovarian cancer. Int J Gynecol Cancer. 3:1993;271-278
36. Rubin S.C., Finstad C.L., Wong G.Y., Almadrones L., Plante M., Lloyd K.O. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol. 168:1993;162-169
37. Singleton T.P., Perrone T., Oakley G., et al. Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage. Cancer. 73:1994;1460-1466
38. Rubin S.C., Finstad C.L., Federici M.G., Scheiner L., Lloyd K.O., Hoskins W.J. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer. 73:1994;1456-1459
39. Felip E., Del Campo J.M., Rubio D., Vidal M.T., Colomer R., Bermejo B. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer. 75:1995;2147-2152
40. Fajac A., Benard J., Lhomme C., et al. c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. Int J Cancer. 64:1995;146-151
41. Medl M., Sevelda P., Czerwenka K., et al. DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer. Gynecol Oncol. 59:1995;321-326
42. Tanner B., Kreutz E., Weikel W., et al. Prognostic significance of c-erB-2 mRNA in ovarian carcinoma. Gynecol Oncol. 62:1996;268-277
43. Beckmann M.W., An H.X., Niederacher D., et al. Oncogene amplification in archival ovarian carcinoma detected by fluorescent differential polymerase chain reaction-a routine analytical approach. Int J Gynecol Cancer. 6:1996;291-297
44. Meden H., Marx D., Roegglen T., Schauer A., Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int J Gynecol Pathol. 17:1998;61-65
45. Hengstler J.G., Lange J., Kett A., et al. Contribution of c-erbB2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res. 59:1999;3206-3214
46. Seki A., Yoshinouchi M., Seki N., Kodama J., Miyagi Y., Kudo T. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. Int J Oncol. 17:2000;103-106
47. Hortobagyi G.N., Ueno N.T., Xia W., et al. Cationic liposomemediated EIA gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol. 19:2001;3422-3433
48. Bookman M.A., Darcy K.M., Clarke-Pearson D., Boothby R.A., Horowitz I.R. Evaluation of monoclonal humanized antiHER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 21:2003;283-290
49. Kaye S., Gershensen D., Hung M.C., Seiden M. Discussion: molecular therapeutics and pharmacogenomics. Gynecol Oncol. 88:2003;S93-S96
50. Arrick B.A., Nathan C.F. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 44:1984;4224-4232
51. Hantigan M.H., Ricketts W.A. Extracellular glutathione is a source of cysteine for cells that express gamma-glutamyl transpeptidase. Biochemistry. 32:1993;6302-6306
52. Richman P.G., Meister A. Regulation of gamma-glutamylcysteine synthetase by nonallosteric feedback inhibition by glutathione. J Biol Chem. 250:1975;1422-1426
53. 2+-dependent cardiac transport system for glutathione S-conjugates. A study using rat heart sarcolemma vesicles. J Biol Chem. 264:1989;17343-17348
54. Ishikawa T., Ali-Osman F. Glutathione-associated cis- diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem. 268:1993;20116-20125
55. Strange R.C., Jones P.W., Fryer A.A. Glutathione-S-transferase: genetics and role in toxicology. Toxicol Lett. 112-113:2000;357-363
56. van der Zee A.G., van Ommen B., Meijer C., Hollema H., van Bladeren P.J., de Vries E.G. Glutathione-S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy. Br J Cancer. 66:1992;930-936
57. Rahilly M., Nafussi A.A., Harrison D.J. Distribution of glutathione-S-transferase isoenzymes in primary epithelial tumors of the ovary. Int J Gynecol Cancer. 1:1991;268-271
58. Murphy D., McGown A.T., Hall A., Cattan A., Crowther D., Fox B.W. Glutathione-S-transferase activity and isoenzyme distribution in ovarian tumour biopsies taken before or after cytotoxic chemotherapy. Br J Cancer. 66:1992;937-942
59. Godwin A.K., Meister A., O'Dwyer P.J., Huang C.S., Hamilton T.C., Anderson M.E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA. 89:1992;3070-3074
60. Mistry P., Kelland L.R., Abel G., Sidhar S., Harrap K.R. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer. 64:1991;215-220
61. Green J.A., Robertson L.J., Clark A.H. Glutathione-S-transferase expression in benign and malignant ovarian tumours. Br J Cancer. 68:1993;235-239
62. Hamada S., Kamada M., Furumoto H., Hirao T., Aono T. Expression of glutathione-S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol. 52:1994;313-319
63. Hirazono K., Shinozuka T., Kuroshima Y., Itoh H., Kawai K. Immunohistochemical expression of glutathione-Stransferase pi (GST-pi) and chemotherapy response in malignant ovarian tumors. J Obstet Gynaecol. 21:1995;305-312
64. Tanner B., Hengstler J.G., Dietrich B., et al. Glutathione, glutathione-S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer. Gynecol Oncol. 65:1997;54-62
65. Ferrandina G., Scambia G., Damia G., et al. Glutathione-Stransferase activity in epithelial ovarian cancer: association with response to chemotherapy and disease outcome. Ann Oncol. 8:1997;343-350
66. Muso H. Long-term prognostic factors for chemotherapy of ovarian cancer. Osaka City Med J. 44:1998;155-171
67. Mayr D., Pannekamp U., Baretton G.B., et al. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas. Pathol Res Pract. 196:2000;469-475
68. Satoh T., Nishida M., Tsunoda H., Kubo T. Expression of glutathione-S-transferase pi (GST pi) in human malignant ovarian tumors. Eur J Obstet Gynecol Reprod Biol. 96:2001;202-208
69. O'Dwyer P.J., Hamilton T.C., LaCreta F.P., et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol. 14:1996;249-256
70. Kavanagh J.J., Spriggs D., Bookman M., et al. Phase 2 study of TLK286 (GST PI-1 activated glutathione analog) in patients with platinum resistant epithelial ovarian cancer. Proc Am Soc Clin Onclol. 2002;831
71. Marks J.R., Davidoff A.M., Kerns B.J., et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 51:1991;2979-2984
72. Kohler M.F., Kerns B.J., Humphrey P.A., Marks J.R., Bast R.C. Jr., Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol. 81:1993;643-650
73. Bosari S., Viale G., Radaelli U., Bossi P., Bonoldi E., Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol. 24:1993;1175-1179
74. Hartmann L.C., Podratz K.C., Keeney G.L., et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol. 12:1994;64-69
75. Niwa K., Itoh M., Murase T., et al. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer. 70:1994;1191-1197
76. Henriksen R., Strang P., Wilander E., Backstrom T., Tribukait B., Oberg K. p53 expression in epithelial ovarian neo-plasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol. 53:1994;301-306
77. Levesque M.A., Katsaros D., Yu H., et al. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer. 75:1995;1327-1338
78. van der Zee A.G., Hollema H., Suurmeijer A.J., et al. Value of P-glycoprotein, glutathione-S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol. 13:1995;70-78
79. Klemi P.J., Pylkkanen L., Kiilholma P., Kurvinen K., Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer. 76:1995;1201-1208
80. Allan L.A., Campbell M.K., Milner B.J., et al. The significance of p53 mutation and over-expression in ovarian cancer prognosis. Int J Gynecol Cancer. 6:1996;483-490
81. Diebold J., Baretton G., Felchner M., et al. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol. 105:1996;341-349
82. Reles A., Schmider A., Press M.F., et al. Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol. 122:1996;489-494
83. Viale G., Maisonneuve P., Bonoldi E., et al. The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients. Ann Oncol. 8:1997;469-476
84. Dong Y., Walsh M.D., McGuckin M.A., et al. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer. 74:1997;407-415
85. Rohlke P., Milde-Langosch K., Weyland C., Pichlmeier U., Jonat W., Loning T. p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 inununoreactivity. J Cancer Res Clin Oncol. 123:1997;496-501
86. Eltabbakh G.H., Belinson J.L., Kennedy A.W., et al. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer. 80:1997;892-898
87. Marx D., Meden H., Ziemek T., Lenthe T., Kuhn W., Schauer A. Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer. Eur J Cancer. 34:1998;845-850
88. Ferrandina G., Fagotti A., Salerno M.G., et al. p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer. 81:1999;733-740
89. Anttila M.A., Kosma V.M., Hongxiu J., et al. p21/WAFT expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer. 79:1999;1870-1878
90. Shahin M.S., Hughes J.H., Sood A.K., Buller R.E. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer. 89:2000;2006-2017
91. Ozalp S.S., Yalcin O.T., Basaran G.N., Artan S., Kabukcuoglu S., Minsin T.H. Prognostic significance of deletion and overexpression of the p53 gene in epithelial ovarian cancer. Eur J Gynaecol Oncol. 21:2000;282-286
92. Gadducci A., Cianci C., Cosio S., et al. p53 status is neither a predictive nor a prognostic variable in patients with ad-vanced ovarian cancer treated with a paclitaxel-based regimen. Anticancer Res. 20:2000;4793-4799
93. Levesque M.A., Katsaros D., Massobrio M., et al. Evidence for a dose-response effect between p53 (but not p21 WAFT/Cipl) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. Clin Cancer Res. 6:2000;3260-3270
94. Skimisdottir I., Sorbe B., Seidal T. P53, bcl-2, and bax: their relationship and effect on prognosis in early stage epithelial ovarian carcinoma. Int J Gynecol Cancer. 11:2001;147-158
95. Howells R.E., Holland T., Dhar K.K., et al. Glutathione-S-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival. Int J Gynecol Cancer. 11:2001;107-112
96. Reles A., Wen W.H., Schmider A., et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 7:2001;2984-2997
97. Fallows S., Price J., Atkinson R.J., Johnston P.G., Hickey I., Russell S.E. P53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol. 194:2001;68-75
98. Geisler H.E., Geisler J.P., Miller G.A., et al. p21 and p53 in ovarian carcinoma: their combined staining is more valuable than either alone. Cancer. 92:2001;781-786
99. Skirnisdottir I., Seidal T., Gerdin E., Sorbe B. The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy. Int J Gynecol Cancer. 12:2002;265-276
100. Berker B., Dunder I., Ensari A., Cengiz S.D. Prognostic value of p53 accumulation in epithelial ovarian carcinomas. Arch Gynecol Obstet. 266:2002;205-209
101. Okuda T., Otsuka J., Sekizawa A., et al. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecol Oncol. 88:2003;318-325
102. Heise C., Lemmon M., Kim D. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin Cancer Res. 6:2000;4908-4914
103. Vasey P.A., Shulman L.N., Campos S., et al. Phase I trial of intraperitoneal injection of the EIB-55-kd-gene-deleted adenovirus ONYX-015 (d11520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol. 20:2002;1562-1569
104. Buller R.E., Runnebaum I.B., Karlan B.Y., et al. A phase 1/11 trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 9:2002;553-566
105. Buller R.E., Shahin M.S., Horowitz J.A., et al. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther. 9:2002;567-572
106. Venter J.C., Adams M.D., Myers E.W., et al. The Sequence of the human genome. Science. 291:2001;1304-1351
107. Simon R., Radmacher M.D., Dobbin K., McShane L.M. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst. 95:2003;14-18
108. Shridhar V., Lee J., Pandita A., et al. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 61:2001;5895-5904
109. Jazaeri A.A., Lu K., Schmandt R., et al. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog. 36:2003;53-59
110. Lancaster J.M., Havrilesky L.J., Whitaker R., et al. Expression array analysis of advanced ovarian cancers distinguishes between short and long-term survivors. Proc Soc Gyn Oncol. 2001;166
111. Wei S.H., Chen C.M., Strathdee G., et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res. 8:2002;2246-2252
112. Sakamoto M., Kondo A., Kawasaki K., et al. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell. 14:2001;305-315
113. Barnholtz-Sloan I.S., Tainsky M.A., Abrams J., et al. Ethnic differences in survival among women with ovarian carcinoma. Cancer. 94:2002;1886-1893
114. 't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536
115. van de Vijver M.J., He Y.D., Van 't Veer L.J., et al. A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med. 347:2002;1999-2009
116. Scambia G., Benedetti P.P., Battaglia F., et al. Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol. 10:1992;529-535
117. van der Burg M.E., Henzen-Logmans S.C., Foekens J.A., et al. The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. Eur J Cancer. 29A:1993;1951-1957
118. Janinis J., Nakopoulou L., Panagos G., Davaris P. Immunohistochemical expression of EGF-R in malignant surface epithelial ovarian neoplasms (SEON). Eur J Gynaecol Oncol. 15:1994;19-23
119. Khater E.M., Ellisi A.G., Hameed M.H.A., Kassim S. Epidermal growth factor receptors in ovarian neoplasms. Cancer Mol Biol. 3:1996;945-954
120. Goff B.A., Ries J.A., Els L.P., Coltrera M.D., Gown A.M. Immunophenotype of ovarian cancer as predictor of clinical out-come: evaluation at primary surgery and second-look procedure. Gynecol Oncol. 70:1998;378-385
121. Ferrandina G., Ranelletti F.O., Lauriola L., et al. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer. Gynecol Oncol. 85:2002;305-310
122. Makar A.P., Holm R., Kristensen G.B., Nesland J.M., Trope C.G. The expression of c-erbB-2 (HER-2/neu) oncogene in invasive ovarian malignancies. Int J Gynecol Cancer. 4:1994;194-199
123. Wong Y.F., Cheung T.H., Lam S.K., et al. Prevalence and significance of HER-2/neu amplification in epithelial ovarian cancer. Gynecol Obstet Invest. 40:1995;209-212
124. Ross J.S., Yang F., Kallakury B.V., Sheehan C.E., Ambros R.A., Muraca P.J. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am J Clin Pathol. 111:1999;311-316
125. Cheng X., Kigawa J., Minagawa Y., et al. Glutathione-S-transferase-pi expression and glutathione concentration in ovarian carcinoma before and after chemotherapy. Cancer. 79:1997;521-527
126. Ghazal-Aswad S., Hogarth L., Hall A.G., et al. The relationship between tumour glutathione concentration, glutathione-S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients. Br J Cancer. 74:1996;468-473
127. Wrigley E.C., McGown A.T., Buckley H., Hall A., Crowther D. Glutathione-S-transferase activity and isoenzyme levels measured by two methods in ovarian cancer, and their value as markers of disease outcome. Br J Cancer. 73:1996;763-769
128. Germain I., Tetn B., Brisson J., Mondor M., Cherian M.G. Markers of chemoresistance in ovarian carcinomas: an immunohistochemical study of 86 cases. Int J Gynecol Pathol. 15:1996;54-62
129. Codegoni A.M., Broggini M., Pitelli M.R., et al. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol. 65:1997;130-137
130. Silvestrini R., Daidone M.G., Veneroni S., et al. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer. 82:1998;159-167
131. Kase H., Kodama S., Nagai E., Tanaka K. Glutathione-S-transferase pi immunostaining of cisplatin-resistant ovarian cancer cells in ascites. Acta Cytol. 42:1998;1397-1402
132. Joncourt F., Buser K., Altermatt H., Bacchi M., Oberli A., Cerny T. Multiple drug resistance parameter expression in ovarian cancer. Gynecol Oncol. 70:1998;176-182
133. Kigawa J., Minagawa Y., Kanamori Y., et al. Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer. Cancer. 82:1998;697-702
134. Yokoyama Y., Sato S., Fukushi Y., Sakamoto T., Futagami M., Saito Y. Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res. 25:1999;387-394
135. Sheridan E., Silcocks P., Smith J., Hancock B.W., Goyns M.H. p53 mutation in a series of epithelial ovarian cancers from the UK, and its prognostic significance. Eur J Cancer. 30A:1994;1701-1704
136. Renninson J., Baker B.W., McGown A.T., et al. Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features. Br J Cancer. 69:1994;609-612
137. Righetti S.C., Della T.G., Pilotti S., et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 56:1996;689-693
138. Herod J.J., Eliopoulos A.G., Warwick J., Niedobitek G., Young L.S., Ker D.J. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 56:1996;2178-2184
139. McMenamin M.E., O'Neill A.J., Gaffney E.F. Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival. Mol Pathol. 50:1997;242-246
140. Geisler J.P., Geisler H.E., Wiemann M.C., Givens S.S., Zhou Z., Miller G.A. Quantification of p53 in epithelial ovarian cancer. Gynecol Oncol. 66:1997;435-438
141. Buttitta F., Marchetti A., Gadducci A., et al. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer. 75:1997;230-235
142. Skomedal H., Kristensen G.B., Abeler V.M., Borresen-Dale A.L., Trope C., Holm R. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. J Pathol. 181:1997;158-165
143. Smith-Sorensen B., Kaern J., Holm R., Dorum A., Trope C., Borresen-Dale A.L. Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer. 78:1998;375-381
144. Shimizu M., Nikaido T., Toki T., Shiozawa T., Fujii S. Clear cell carcinoma has an expression pattern of cell cycle regulatory molecules that is unique among ovarian adenocarcinomas. Cancer. 85:1999;669-677
145. Wen W.H., Reles A., Runnebaum I.B., et al. p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol. 18:1999;29-41
146. Daponte A., Guidozi F., Tiltman A.J., Marineanu A., Taylor L. p53 as a prognostic factor for stage III serous adenocarcinoma of the ovary. Anticancer Res. 19:1999;2387-2389
147. Schmider A., Gee C., Friedmann W., et al. p21 (WAFI/CIPI) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma. Gynecol Oncol. 77:2000;237-242
148. Laframboise S., Chapman W., McLaughlin J., Andrulis I.L. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance. Cancer J. 6:2000;302-308
149. Geisler J.P., Geisler H.E., Miller G.A., Wiemann M.C., Zhou Z., Crabtree W. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months. Gynecol Oncol. 77:2000;278-282
150. Lavarino C., Pilotti S., Oggionni M., et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol. 18:2000;3936-3945
151. Schuyer M., van der Burg M.E., Henzen-Logmans S.C., et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer. 85:2001;1359-1367
152. Sagarra R.A., Andrade L.A., Martinez E.Z., Pinto G.A., Syrjanen K.J., Derchain S.F. P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer. Int J Gynecol Cancer. 12:2002;720-727
153. Kupryjanczyk J., Szymanska T., Madry R., et al. Evaluation of clinical significance of TP53, BCL-2, BAX and MEKI expression in 229 ovarian carcinomas treated with platinumbased regimen. Br J Cancer. 88:2003;848-854